Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sage Therapeutic Com
(NQ:
SAGE
)
5.170
+0.320 (+6.60%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sage Therapeutic Com
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S.
December 28, 2021
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
5 Value Stocks In The Healthcare Sector
December 27, 2021
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E...
Via
Benzinga
Where Sage Therapeutics Stands With Analysts
December 20, 2021
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE...
Via
Benzinga
Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises
December 14, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
December 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Earnings Scheduled For November 2, 2021
November 02, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...
Via
Benzinga
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
December 08, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
5 Value Stocks To Watch In The Healthcare Sector
December 06, 2021
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples...
Via
Benzinga
Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients
December 01, 2021
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone...
Via
Benzinga
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
December 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
December 01, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Host Sage FutureCast Webcast
November 29, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 24, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
November 11, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
November 08, 2021
Gainers Kiromic BioPharma (NASDAQ:KRBP) ...
Via
Benzinga
What 8 Analyst Ratings Have To Say About Sage Therapeutics
November 03, 2021
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings ...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
November 03, 2021
Needham boosted Paycom Software, Inc. (NYSE:PAYC) ...
Via
Benzinga
Sage Therapeutics Inc (SAGE) Q3 2021 Earnings Call Transcript
November 02, 2021
SAGE earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
How Bad Are Sage Therapeutics's Earnings? | Return On Capital Employed
November 02, 2021
Sage Therapeutics (NASDAQ:SAGE) brought in sales totaling $1.44 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 21.17%, resulting in a...
Via
Benzinga
Artificial Intelligence Could Be About To Replace Your Doctor
November 02, 2021
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
November 02, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Preview: Sage Therapeutics's Earnings
November 01, 2021
Sage Therapeutics (NASDAQ:SAGE) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
October 27, 2021
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been...
Via
FinancialNewsMedia
Exposures
Product Safety
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
B. Riley Sees 'Significant Potential' In This Beaten-Up Biotech Stock
October 21, 2021
B. Riley analyst calls Seelos Therapeutics Inc (NASDAQ:
Via
Benzinga
Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
October 20, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
What 7 Analyst Ratings Have To Say About Sage Therapeutics
October 20, 2021
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings...
Via
Benzinga
Abbot Labs and Biogen Outshine Novavax in the Health Care Sector
October 20, 2021
Just before Tuesday’s close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
October 20, 2021
Mizuho cut QUALCOMM Incorporated (NASDAQ: QCOM) price target from $180 to $165. QUALCOMM shares fell 0.3% to $132.13 in pre-market trading. Deutsche Bank raised the price...
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.